AXIOS June 4, 2024
Tina Reed

The evidence of new obesity and diabetes drugs’ smashing success can now be seen in grocery store aisles.

Why it matters: Food giants are rolling out new and reformulated products appealing to the changing appetites of the fast-growing number of people prescribed drugs like Novo Nordisk’s Ozempic and Wegovy — and experts say this could shift American diets more broadly.

The big picture: It’s thought the drugs known as GLP-1 agonists help patients lose weight by slowing down stomach emptying, allowing them to get full faster and for longer.

  • But that can also make it harder to get necessary nutrients, experts say.
  • GLP-1 users also have reported changing tastes, with high-fat and sweet foods becoming less appealing for some.
  • ...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider, Retailer
Is Generative AI The New Hero Of Your Consumer Products And Retail Business?
Northwell Health partners with Instacart to bolster food access
When the Disruptors are Disrupted: Why Retailers are Tapping Out
Stores sold in Kroger, Albertsons merger to keep pharmacy, healthcare services
Walmart continues to adopt gen AI, while still keeping humans in the loop

Share This Article